My research focuses on understanding the nature of human haematopoietic stem cells (HSCs) and developing new method to maintain and expand these cells ex vivo for clinical transplantation, which when combined with genome editing techniques, will permit the correction of monogenic disorders (e.g. sickle cell disease and thalassaemias) in autologous cells.
I received my Ph.D degree at University of Sheffield on regenerative medicine in 2015. I'm current a postdoc researcher in MRC Molecular Haematology Unit.
The BET inhibitor CPI203 promotes ex vivo expansion of cord blood long-term repopulating HSCs and megakaryocytes.
Hua P. et al, (2020), Blood
Single-cell analysis of bone marrow-derived CD34+ cells from children with sickle cell disease and thalassemia.
Hua P. et al, (2019), Blood, 134, 2111 - 2115